Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

COMMUNITY

411 - CANADIAN PERSPECTIVES ON LATE BREAKING CLINICAL TRIALS

Sunday, October 27, 2024
8:00 AM – 9:00 AM PT
Room: 114-115
This webinar will focus on the latest research findings from international meetings in 2024. These perspectives can impact profound changes and improvements in their clinical approach.

The four trials being discussed will be:
ARTESiA - Presenter TBC
STEP HFpEF - Dr. Subodh Verma
FINEARTS - Dr. Jacob Udell
Helios - Dr. Diego Delgado

Each trial presentation will be followed by a period of clinical application and panel discussion.

Learning Objectives:

At the end of this session participants will be able to:
  • describe evidence supporting new therapies in clinical care;
  • critically appraise recent landmark trials; and
  • identify knowledge gaps requiring further study.
Disclosure(s):
William F. McIntyre, MD: Atricure: Consultant/Advisory Board (Ongoing); iRhythm: Speaker/Honoraria (Ongoing); Trimedics: consulting (Ongoing), research grants (Ongoing)
Anil Gupta, MD, FRCPC: No financial relationships to disclose
Subodh Verma, MD PhD FRCSC FAHA FCCS FCAHS: Amarin: Speaker/Honoraria (Ongoing); Amgen: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Astrazeneca: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Canadian Medical and Surgical Knowledge Translation Research Group: Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); HLS Therapeutics: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Humber River Health: Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Merck: Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); PhaseBio: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); S & L Solutions Event Management Inc: Speaker/Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Sun Pharma: Speaker/Honoraria (Ongoing)
Margot K. Davis, MD, MSc, FRCPC: Abbott: Speaking honoraria (Ongoing); Alnylam: advisory board honoraria (Ongoing); Anthos: Ad board honoraria (Ongoing); AstraZeneca: Ad board honoraria (Ongoing), Research steering committee, research funding (Ongoing); BI-Lilly: Ad board honoraria (Ongoing); Ferring: Ad board honoraria (Ongoing), Speaking honoraria (Ongoing); Janssen: Ad board honoraria (Ongoing), Consulting and speaking honoraria (Ongoing), Research funding (Ongoing); Jazz Pharmaceuticals: Ad board honoraria (Ongoing); Novo Nordisk: Advisory board honoraria (Ongoing), Consulting fees (Ongoing); Pfizer: consulting honoraria (Ongoing), research funding (Ongoing), speaking and consulting honoraria (Ongoing)
Jacob A. Udell, MD, MPH: Amgen: Speaker/Honoraria (Terminated, July 31, 2023); AstraZeneca: Speaker/Honoraria (Terminated, May 31, 2023); Bayer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Terminated, July 31, 2024), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, July 31, 2024), Speaker/Honoraria (Terminated, July 31, 2024); Eli Lilly and Company: Speaker/Honoraria (Terminated, July 31, 2023); GlaxoSmithKline: Consultant/Advisory Board (Terminated, September 2, 2024), Speaker/Honoraria (Terminated, September 2, 2024); Janssen: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, December 31, 2022); Novartis: Consultant/Advisory Board (Terminated, January 31, 2021); Novavax: Consultant/Advisory Board (Terminated, January 31, 2023); Novo Nordisk: Consultant/Advisory Board (Ongoing); Sanofi: Consultant/Advisory Board (Terminated, December 31, 2022), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, December 31, 2022), Speaker/Honoraria (Terminated, December 31, 2022)
Diego Delgado, MD, MSc: No financial relationships to disclose